Tuesday, January 18, 2022

Breakthrough transplant hints big opportunity

Right now, big tech companies are investing money in healthcare startups. Google (NASDAQ:GOOGNasdaq:Google, Apple (NASDAQ:AAPL, Oracle (NYSE:orcl, heroine (NASDAQ:AMZN) And Microsoft (NASDAQ:MSFT) investing in and acquiring healthcare companies like they’ve never done before…

Source: shutterstock.com/MAD.vertize

This is a great clue for investors who want to stay ahead of trends in venture capital deals.

As I said in December:

“Given the trend of acquisitions of major companies, we can not only look to the future to see where the trends are headed, but position ourselves as investors on a path of progress.”

Knowing that there are big buyers out there (big tech), private health care investments will likely perform well for the foreseeable future.

But what if we can invest in opportunities before the big players get involved?

What signs can we see that indicate that an industry is about to take off… but still small enough to be positioned for massive profits in the years to come?

That’s what we have right now in the longevity space.

long life investment This is going to be one of the biggest investment trends we’ve ever seen.

And while this longevity boom leads to growth, the world is going to change in ways you might not believe…

Interspecies transplant could become the norm

The world’s “first transplant of a genetically modified pig heart for acceptance into the human body” was performed last week. And, so far, it has been a success.

The procedure was performed at the University of Maryland Medical Center on a 57-year-old man who was ineligible for a traditional human-to-human transplant because of his poor health.

“It was either die or do this procedure,” said the man who received the pig heart and whose body has accepted the transplanted heart without rejection.

It came just months after doctors at NYU Langone Health in New York City announced that they had successfully transplanted a pig kidney into a human.

Both procedures were experimental and required special permission from US medical regulators.

You see, xenotransplantation, which is the field of cross-species organ transplantation, has previously been impossible because “transferring an organ from one animal species to another provokes a violent and immediate attack from the host’s immune system,” According to Science magazine.

However, in the two xenotransplants I just mentioned, those organs were genetically modified to exclude certain genes that the human body normally rejects. This allows the human body to “cheat” into accepting and using foreign organs as if they were from another human.

With two successful (so far) transplants, there are plans to begin clinical trials for this new type of organ transplant technology.

The process of modifying genes within pig organs is just scratching the surface that several biotech companies are now researching…

You have probably heard about gene editing. Gene editing is the process of altering the DNA sequencing of an organism. This technology allows the addition, removal or replacement of genetic material to serve a variety of purposes, such as the transplantation of organs from one species to another.

The impact of gene editing on our human species (and all other organisms with DNA) is difficult to understand. Theoretically, by editing DNA, we could do anything from curing cancer to improving eyesight to living longer.

And living long is something that people are willing to pay big bucks for.

private money is poured

Last month, Corify Capital, a new venture capital fund, announced that it would be investing $100 million in longevity startup companies.

“corify” It joins several other investors in the longevity space, including Berlin-based VC and company builder Apollo Health Ventures, which successfully raised $180 million in funding in November. The other two are Swiss longevity company manufacturer Maximon, which has recently launched a CHF 100 million ($108 million) investment, and the Longevity Science Foundation of Switzerland, which has set up to allocate $1 billion over 10 years to longevity research. has committed.

Other investment funds and holding companies that together have raised billions of dollars include:

The launch of these funds and many others shows that there is a huge amount of interest and money that is starting to support longevity science.

These investment funds will enable startup biotech companies to develop life-changing technologies. As breakthroughs like xenotransplantation become more common in health care, we are going to see a huge amount of money flow into this industry.

As venture capitalists, we can see this trend in its infancy and start establishing itself right now.

through my premium service Venture Capital Investor (Ready to launch publicly in the coming months), we’ve already made an investment in a private longevity company that’s positioned to generate massive returns for investors…

And I’ll keep my eye out for more soon.

At the date of publication, Cody Shirk had no position (directly or indirectly) in the securities mentioned in this article. The views expressed in this article are those of the author, who is subject to InvestorPlace.com Publication Guidelines,

By focusing on megatrends shaping the future, Cody Shirk uncovers generational wealth in the private investment sector. To make sure you never miss Venture Capital Digest, click here to subscribe.

Nation World News Deskhttps://nationworldnews.com
Nation World News is the fastest emerging news website covering all the latest news, world’s top stories, science news entertainment sports cricket’s latest discoveries, new technology gadgets, politics news, and more.
Latest news
Related news
- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here